Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Stock Price Down 1.7% – What’s Next?

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR)’s stock price fell 1.7% on Monday . The stock traded as low as $23.92 and last traded at $24.02. 1,456 shares changed hands during trading, a decline of 30% from the average session volume of 2,080 shares. The stock had previously closed at $24.43.

Amplify Weight Loss Drug & Treatment ETF Stock Up 1.2%

The firm’s 50 day moving average price is $24.47 and its two-hundred day moving average price is $25.17. The firm has a market capitalization of $4.15 million, a PE ratio of 24.31 and a beta of 0.40.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC acquired a new position in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned approximately 10.02% of Amplify Weight Loss Drug & Treatment ETF at the end of the most recent reporting period.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.